The suppression of premature termination codons and the repair of splicing mutations in CFTR

[1]  D. Bedwell,et al.  Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences , 2017, Human molecular genetics.

[2]  Raman Agrawal,et al.  Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases , 2017, Cell and Tissue Research.

[3]  G. Lukács,et al.  Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product*♦ , 2016, The Journal of Biological Chemistry.

[4]  D. Bedwell,et al.  Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. , 2016, American journal of respiratory and critical care medicine.

[5]  O. Namy,et al.  New Pharmacological Approaches to Treat Patients with Cystic Fibrosis with Nonsense Mutations. , 2016, American journal of respiratory and critical care medicine.

[6]  A. Jacobson,et al.  Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression , 2016, Proceedings of the National Academy of Sciences.

[7]  Hugo M. Botelho,et al.  Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides , 2016, Human mutation.

[8]  A. Krainer,et al.  Antisense-oligonucleotide-directed inhibition of nonsense-mediated mRNA decay , 2015, Nature Biotechnology.

[9]  I. Sermet-Gaudelus,et al.  Biosynthesis of cystic fibrosis transmembrane conductance regulator. , 2014, The international journal of biochemistry & cell biology.

[10]  B. Kerem,et al.  The unfolded protein response affects readthrough of premature termination codons , 2014, EMBO molecular medicine.

[11]  J. Schacht,et al.  Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. , 2014, American journal of respiratory cell and molecular biology.

[12]  L. Galietta,et al.  Alternative Splicing of In‐Frame Exon Associated with Premature Termination Codons: Implications for Readthrough Therapies , 2013, Human mutation.

[13]  K. Mamchaoui,et al.  Rescue of nonsense mutations by amlexanox in human cells , 2012, Orphanet Journal of Rare Diseases.

[14]  D. Bedwell,et al.  Suppression of premature termination codons as a therapeutic approach , 2012, Critical reviews in biochemistry and molecular biology.

[15]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[16]  P. Walter,et al.  The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation , 2011, Science.

[17]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[18]  Jordan Wengrod,et al.  Overexpression of the c-myc Oncogene Inhibits Nonsense-mediated RNA Decay in B Lymphocytes* , 2011, The Journal of Biological Chemistry.

[19]  Z. Bebők,et al.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54 , 2011, Journal of Molecular Medicine.

[20]  J. Zavadil,et al.  Inhibition of Nonsense-Mediated RNA Decay by the Tumor Microenvironment Promotes Tumorigenesis , 2011, Molecular and Cellular Biology.

[21]  F. Vermeulen,et al.  Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.

[22]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[23]  Eitan Kerem,et al.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.

[24]  J. Gécz,et al.  Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation , 2007, Nature Genetics.

[25]  B. Kerem,et al.  The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells , 2007, European Journal of Human Genetics.

[26]  R. Gibson,et al.  No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. , 2007, American journal of respiratory cell and molecular biology.

[27]  D. Cane,et al.  The nonsense-mediated decay RNA surveillance pathway. , 2007, Annual review of biochemistry.

[28]  J. Karras,et al.  Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-Responsiveness in Allergic Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[30]  J. Rousset,et al.  In vitro prediction of stop-codon suppression by intravenous gentamicin patients with cystic fibrosis : a pilot study , 2022 .

[31]  B. Kerem,et al.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. , 2007, The Journal of clinical investigation.

[32]  R. Kellermayer.  Translational readthrough induction of pathogenic nonsense mutations. , 2006, European journal of medical genetics.

[33]  B. Kerem,et al.  Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation , 2004, EMBO reports.

[34]  E. Kerem.  Pharmacologic therapy for stop mutations: how much CFTR activity is enough? , 2004, Current opinion in pulmonary medicine.

[35]  Francisco Martinez-Murillo,et al.  Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise , 2004, Nature Genetics.

[36]  M. Garcia-Blanco,et al.  Alternative splicing in disease and therapy , 2004, Nature Biotechnology.

[37]  J. Rousset,et al.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment , 2004, Gene Therapy.

[38]  L. Maquat.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[39]  K. Heller,et al.  Sequence information for the splicing of human pre-mRNA identified by support vector machine classification. , 2003, Genome research.

[40]  D. Black.  Mechanisms of alternative pre-messenger RNA splicing. , 2003, Annual review of biochemistry.

[41]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[42]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[43]  Teresa Casals,et al.  New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. , 2003, Human molecular genetics.

[44]  T. Cooper,et al.  Pre-mRNA splicing and human disease. , 2003, Genes & development.

[45]  M. Amaral,et al.  Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. , 2002, American journal of respiratory cell and molecular biology.

[46]  A. Krainer,et al.  Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.

[47]  B. Kerem,et al.  Splicing regulation as a potential genetic modifier. , 2002, Trends in genetics : TIG.

[48]  L. Chasin,et al.  Human Genomic Sequences That Inhibit Splicing , 2000, Molecular and Cellular Biology.

[49]  M. Knowles,et al.  Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[50]  B. Kerem,et al.  The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation. , 1998, Genomics.

[51]  P. Wong,et al.  Identification of a splice site mutation in the cystathionine beta-synthase gene resulting in variable and novel splicing defects of pre-mRNA. , 1997, Biochemical and molecular medicine.

[52]  L. Maquat.  When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. , 1995, RNA.

[53]  M Claustres,et al.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. , 1995, The New England journal of medicine.

[54]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[55]  B. Kerem,et al.  The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. , 1997, American journal of human genetics.

[56]  J C Olsen,et al.  Identification of a splice site mutation (2789+5 G>A) associated with small amounts of normal CFTRmRNA and mild cystic fibrosis , 1997, Human mutation.

[57]  J. Kaplan,et al.  Analysis of Alternative Splicing Patterns in the Cystic Fibrosis Transmembrane Conductance Regulator Gene Using mRNA Derived from Lymphoblastoid Cells of Cystic Fibrosis Patients , 1996, European journal of human genetics : EJHG.

[58]  B. Kerem,et al.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. , 1992, American journal of human genetics.

[59]  R. Amann,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2022 .